Peer-reviewed research conducted by the National Pharmaceutical Council (NPC) and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on what’s behind discrepancies in coverage decisions from one insurer to the next.
Dose optimization strategies offer a potentially valid, clinically based intervention in which payers can realize a direct drug cost savings, and indirect medical cost avoidance.
Adoption of digital and focus on value set to transform current prior authorization processes.
Specialty medications also are the fastest growing cost component of total health care costs.
Patients can benefit significantly by having support throughout their treatment journey, starting with access and minimizing financial barriers.
Our specialty pharmacy readers are amongst the most informed in health care.
Data from 2 studies evaluating guselkumab (Tremfya, Janssen) in active psoriatic arthritis were presented at the American College of Rheumatology and Association of Rheumatology Professionals 2019 Annual Meeting.
